Intec Parent

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Indaptus Therapeutics

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus.

Intec Closes Merger with Decoy Biosystems

JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ: NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently expected to close after market hours today, Tuesday, August 3, 2021, subject to satisfaction or waiver of all closing conditions. Immediately following the closing, the combined company will be renamed "Indaptus Therapeutics, Inc.", and is expected to begin trading on The Nasdaq Capital Market under the new ticker symbol "INDP" upon the commencement of trading on Wednesday, August 4, 2021.

Intec Announces Expected Closing Date of Decoy Merger

NTEC stock is riding high today without any news. It seems investors are getting hyped up ahead of its merger with Decoy Biosystems.

NTEC Stock: 10 Things to Know About Red-Hot Intec Pharma

GT Biopharma Inc

PAVmed

These Former Penny Stocks Are Turning Heads Ahead Of Robinhood IPO The post 3 Biotech Penny Stocks To Watch On Robinhood IPO Day appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch On Robinhood IPO Day

JERUSALEM, July 26, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec Israel" or the "Company"), today announced that its wholly-owned subsidiary, Intec Parent, Inc. ("Intec US"), entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement.

Intec Announces $30 Million Private Placement Ahead of Decoy Merger

1847 GOEDEKER INC.

9 Meters Biopharma

Oragenics

These hot penny stocks may deserve a place on your watchlist this month The post Hot Penny Stocks to Buy Now? 4 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Now? 4 You Need to Know About

Eastside Distilling

Evogene

OrganiGram Holdings Inc.

Marijuana legalization is a hot topic & some penny stocks are benefiting in 2021. The post Best Penny Stocks To Buy Before Marijuana Legalization?

Best Penny Stocks To Buy Before Marijuana Legalization? 4 To Watch Now

Adial Pharmaceuticals Inc

MediciNova

OPKO Health

vTv Therapeutics

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 10 Biotech Penny Stocks to Watch in July 2021

Aeterna Zentaris

Amarin Corporation Plc

DURECT

Globus Maritime

CarLotz

MediWound

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 To Watch This Week

Ambev

Cinedigm

Looking for Reddit penny stocks to buy? Check these 3 out The post Hot Reddit Penny Stocks to Buy?

Hot Reddit Penny Stocks to Buy? Check These 3 Out

Corbus Pharmaceuticals Holdings

Greenlane Holdings

FSD Pharma

Innovative Industrial Properties

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

The Week Where New York Legalizes Recreational Marijuana

NEW YORK, March 26, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Intec Pharma Ltd. ("NTEC" or the "Company") (NTEC) relating to its proposed merger with Decoy Biosystems.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTEC

NEW YORK, March 22, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intec Pharma Ltd.  ("Intec" or the "Company") (NASDAQ: NTEC) in connection with the proposed acquisition of the Company by Decoy Biosystems, Inc.("Decoy").

SHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.

HEXO Corp

SNDL Inc.

Village Farms International

cbdMD Inc

Last Week's 7 Biggest Cannabis Moves

JERUSALEM , March 16, 2021 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that it has filed its annual report on Form 10-K for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on Intec's website, www.intecpharma.com, by selecting “Investors” and then “Financials” and “SEC Filings”.

Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K

The stock price of Intec Pharma Ltd (NASDAQ: NTEC) increased by over 80% pre-market. This is why it happened.

NTEC Stock Price Increases Over 80% Pre-Market: Why It Happened

JERUSALEM, March 15, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.

Intec Pharma and Decoy Biosystems Announce Merger Agreement

Shares of Intec Pharma Ltd (NASDAQ:NTEC) surged today as it went from $3.46 per share yesterday to a day high of $7.12 -- which imputes a jump of 105.78%. This is why it happened.

Intec Pharma (NTEC) Stock Price Jumped Over 100%: Why It Happened

Shares of NTEC stock are soaring on Wednesday after Intec Pharma announced a cannabinoid research collaboration with GW Pharma. The post Intec Pharma News: Why NTEC Stock Is on Fire Today appeared first on InvestorPlace.

Intec Pharma News: Why NTEC Stock Is on Fire Today

JERUSALEM, Nov. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update. "We maintain our focus on executing strategic partnerships and...

Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update

JERUSALEM, Oct. 8, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We...

Intec Pharma Announces New Research Collaboration Agreement with MSD

JERUSALEM, Sept. 14, 2020 /PRNewswire/ -- Intec Pharma Ltd.

Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

JERUSALEM, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offering, of 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3511 per share, and pre-funded warrants to purchase 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3411 per warrant, which represents the per warrant offering price less the $0.01 per share exercise price for each such warrant. The offering is expected to close on or about August 10, 2020, subject to satisfaction of customary closing conditions.

Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering

JERUSALEM, Aug. 5, 2020 /PRNewswire/ -- Intec Pharma Ltd.

Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Intec Pharma Ltd. (NTEC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Intec Pharma Ltd. (NTEC) Upgraded to Strong Buy: Here's Why

News for Intec Parent Stock (NTEC)